Corrective Phases R...
Health Care: Drugs
Cell Therapeutics Inc. (CTIC: NASDAQ)
$0.86 -0.03 | -3.86%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 5.42 | 0.58 | 0.98 |
| Price to Sales (TTM) | 0.00 | 4.62 | 1.42 |
| Price to Book (MRQ) | 15.18 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 15.18 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -2.30 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -3.40 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.80 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 2.10 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.27 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.31 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -969.54 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | n.a. | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -136.10 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -172.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | -364.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -721.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 0.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -632,337.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with CTIC
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- User2012 stock
- ContributorCancer Drug Stocks to Trade...
- UserImagine!
- Userfrankiesun09@gmail.com
- UserASCO 2010
- Contributor10 Biotech Stocks Facing FD...
- Userbiotech121
- UserJswaim
- UserSLITraders
Latest CTIC Headlines from TheStreet
- Cell Therapeutics Juggles Chainsaws To Distract Investors From Its Dead-End Course 04.19.12 | 03:04 pm
- The 5 Dumbest Things on Wall Street This Week: Feb. 3 02.03.12 | 06:02 am
- The 5 Dumbest Things on Wall Street: Feb. 3
02.03.12 | 05:02 am - Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances 01.30.12 | 05:01 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- The Worst Biotech CEO of 2011 Is ... 12.09.11 | 07:12 am
- Biotech Stock Mailbag: Affymax 12.02.11 | 06:12 am
- 22 Hot Drugs Facing FDA Approval in 2012 11.29.11 | 08:11 am
- 10 Best Mutual Funds for 2012 11.16.11 | 07:11 am
Press Releases for CTIC
- Cell Therapeutics Completes Acquisition Of Pacritinib A Highly Selective JAK2 Inhibitor - PR Newswire 06.04.12 | 01:06 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 06.01.12 | 04:06 pm
- Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published In The Lancet Oncology - PR Newswire 05.31.12 | 01:05 am
- Cell Therapeutics' Aequus BioPharma Validates Its Proprietary GlycoPolymer Technology For The Extension Of The Half-life Of Therapeutic Protein Drugs - PR Newswire 05.30.12 | 01:05 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 05.29.12 | 04:05 pm
- Cell Therapeutics Announces Institutional Investor To Purchase $40 Million Of Convertible Preferred Stock And Warrants To Purchase Common Stock - PR Newswire 05.29.12 | 03:05 am
- Cell Therapeutics' Pixuvri® Approved In European Union As Monotherapy To Treat Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas - PR Newswire 05.10.12 | 02:05 pm
- Cell Therapeutics Enters Into Agreement To Acquire Pacritinib, A Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate For Myelofibrosis - PR Newswire 04.19.12 | 01:04 am
- University Of Washington's Neuro-Oncology Program To Investigate Cell Therapeutics' Drug Candidate OPAXIO⢠(Paclitaxel Poliglumex) Plus Radiotherapy For Glioblastoma Multiforme, A Highly Malignant Brain Cancer - PR Newswire 03.27.12 | 01:03 am
- European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri⢠- PR Newswire 02.17.12 | 07:02 am
Partner Headlines for CTIC
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- Cell Therapeutics Plummeting on NDA Withdrawl - Benzinga 01.30.12 | 09:01 am
- US Panel to Review CTIC's Pixantrone - Analyst Blog - Zacks 01.04.12 | 10:01 am
- Mid-Day Update: Stocks Higher; Investors Cheer European Fiscal Deal - NASDAQ 12.09.11 | 05:12 pm
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.11.11 | 09:11 am
- CTIC Loss Widens, Resubmits NDA - Analyst Blog - Zacks 10.27.11 | 10:10 am
- 19 Small Cap Stocks Boosted By Institutional Buying - Seeking Alpha 10.11.11 | 08:10 am
- Cell Therapeutics Efforts Validated - Analyst Blog - Zacks 10.07.11 | 04:10 pm
- Morning Market Movers - Benzinga 08.31.11 | 09:08 am
